Conflicts of Interest Not Listed in Practice Parameters

ADHD

  • Russell Barkley, Ph.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Eli Lilly and Company, Shire Pharmaceuticals Group plc, and McNeil Pediatrics. Dr. Barkley also has or has had books/intellectual property with Guilford Publications.
  • Joe Biederman, M.D.: receives or has received research support, served on a speaker’s bureau, or has been on the advisory board: Shire Pharmaceuticals Group plc, Eli Lilly and Company, Pfizer, Inc., McNeil, Abbott, Bristol-Myers-Squibb, New River Pharmaceuticals, Cephalon, Janssen, L.P., Novartis Pharmaceuticals, UCB Pharma, Astra-Zeneca, Forest Laboratories, Glaxo-SmithKline and Neurosearch. He has also received private foundation research support from: Stanley Medical Institute, Inc, Lilly Foundation, Prechter Foundation and from NIMH, NICHD, and NIDA.
  • Caryn Carlson, Ph.D.: no conflicts of interest to disclose
  • Mina Dulcan, M.D.: serves or has served in a governance position for Eli Lilly and Company (Strattera Global Advisory Board) and APIRE. Dr. Dulcan also serves or has served as a consultant for Comprehensive NueroScience, Inc. She also is an author/editor and member of the Editorial Advisory Board for American Psychiatric Publishing, Inc.
  • Gregory Fabiano, M.A.: no conflicts of interest to disclose
  • Joan Gerring, M.D.: no conflicts of interest to disclose
  • Larry Greenhill, M.D.:
    • Eli Lilly: Consultant; Member of the Data Mining Board; Author on papers with employees of Eli Lilly; Support for travel to IACAPAP meeting in Australia; potential support for travel and planning meetings for ESCAP meetings in Florence, Italy.
    • Novartis: Honorarium to attend two scientific advisory boards; Signed contract to accept support for research at my institution, but no patients were recruited because study closed before contract negotiations were complete.
    • New River Pharmaceuticals: Signed contract to accept support for research at my institution, but no patients were recruited because study closed before contract negotiations were complete.
    • McNeil Pharmaceuticals: Signed contract to accept support for research at my institution, but no patients were recruited because study closed before contract negotiations were complete.
    • Forest Pharmaceuticals: Signed contract to accept support for research at my institution, but no patients were recruited because study closed before contract negotiations were complete.
    • Otsuka Pharmaceuticals: Received support for a research contracts in the form of payment to generate similar appearing active drug and placebo.
    • Pfizer: Received honorarium to lecture at a Pfizer investigator meeting and for work as chairman of the Ziprasidone Pediatric Data Safety and Monitoring Board.
    • Janzen-Cilag: Received honorarium to give a 2 hour seminar in Melbourne Australia to practitioners.
    • Johnson and Johnson: Received honorarium to participate in a phone call for a Scientific Advisory Panel.
  • Paul Hammerness, M.D.: serves or has served on speaker’s bureau for Shire Pharmaceuticals Group plc and contributes to Medscape.
  • Lily Hechtman, M.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Eli Lilly and Company, Janssen, L.P., Purdue, and Shire Pharmaceuticals Group plc. Dr. Hechtman also serves or has served in a governance position with CADDRA (Canadian ADHD Resource Alliance).
  • Catherine Jaselskis, M.D.: no conflicts of interest to disclose
  • Guy Palmes, M.D.: serves on speakers bureau for McNeil Pediatrics
  • William Pelham, Ph.D.: TBD
  • Cynthia W. Santos, M.D.: serves in governance position at ABPN
  • Thomas Spencer, M.D.: TBD
  • James Swanson, Ph.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for McNeil, UCB, Eli Lilly and Company, Cephalon, Janssen, L.P., and Novartis Pharmaceuticals.
  • Daniel Waschbusch, Ph.D.: receives or has received research support from Eli Lilly and Company
  • Timothy Wilens, M.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Abbott Laboratories, Cephalon, Ortho-McNeil, Eli Lilly and Company, National Institute on Drug Abuse, Neurosearch, Shire Laboratories, Inc., Novartis Pharmaceuticals, Janssen, L.P., National Institute on Mental Health, and Pfizer, Inc.

Atypical Antipsychotics

  • Sanjiv Kumra, M.D.: serves or has served as an advisor/consultant for AstraZeneca, Schering Plough, and Bristol-Myers Squibb. He has received research funding from Schering Plough.
  • Richard Malone, M.D.: serves or has served as an advisor/consultant for the NIMH and FDA. He has received research funding from Lilly, Bristol-Myers Squibb, the NIMH and FDA. He is a clinical trial site for Johnson & Johnson.
  • Vivian Kafantaris, M.D.: has or has received research funding from Eli Lilly, GlaxoSmithKline, AstraZeneca, Janssen, and Pfizer.
  • Jon McClellan, M.D.: has no financial conflicts of interest to disclose.
  • Christopher McDougle, M.D.: has or has received research funding from Bristol-Myers Squibb, Fragile X Research Foundation, and the NIMH. He serves or has served as an advisor/consultant for Bristol-Myers Squibb Co., Forest Research Institute, and F. Hoffman LaRoche, Ltd. He serves or has served on a speakers bureau for Bristol-Myers Squibb, Co.
  • Sherry Barron-Seabrook, M.D.: has no financial conflicts of interest to disclose.
  • Gail Edelsohn, M.D.; has no financial conflicts of interest to disclose.
  • David R. DeMaso, M.D.: has or has received research funding from the NIMH and NHLBI. He has intellectual property with APPI.
  • Melvin Oatis, M.D.: serves or has served as an advisor/consultant and on a speakers bureau to Shire, McNeil, and Novartis

Autism

  • Andres Martin, M.D.: serves as editor-in-chief of the Journal of the American Academy of Child and Adolescent Psychiatry, for which he receives a stipend. He has intellectual property with, and receives royalties from, Wolters Kluwer.
  • Schuyler Henderson, M.D.: has no financial conflicts of interest to disclose.
  • Rhea Paul, M.D.: has intellectual property with Brookes Publishing; Elsevier B.V, Erlbaum Publishers; Plural Publishers, Inc.; and John Wiley & Sons, Inc.
  • Christopher McDougle, M.D.: has or has received research funding from Bristol-Myers Squibb, Fragile X Research Foundation, and the NIMH. He serves or has served as an advisor/consultant for Bristol-Myers Squibb Co., Forest Research Institute, and F. Hoffman LaRoche, Ltd. He serves or has served on a speakers bureau for Bristol-Myers Squibb, Co.
  • Ami Klin, Ph.D.: has no financial conflicts of interest to disclose.
  • Connie Zajicek, M.D.: has no financial conflicts of interest to disclose.
  • Louis Kraus, M.D.: serves on the Commission to End Health Care Disparities, AMA Council on Children, Adolescents and Their Families, APA. He serves or has served as a forensic advisor/consultant to Eli Lilly.
  • Tami Benton, M.D.: has no financial conflicts of interest to disclose.
  • Syed Naqvi, M.D.: has no financial conflicts of interest to disclose.
  • Bryan King, M.D.: has no financial conflicts of interest to disclose.
  • Melissa Del Bello, M.D.: serves on the ACNP publication committee. She has or has received research funding from AstraZeneca, Eli Lilly, Johnson and Johnson, Janssen, Pfizer, Otsuka, Sumitomo, NIDA, NIMH, NIAAA, NARSAD, GlaxoSmithKline, Merck, Novartis, and Lundbeck. She serves or has served as a consultant/advisor to Pfizer, Merck, Schering-Plough. She serves or has served on a speakers bureau for Merck and Bristol-Myers Squibb.
  • Doug Novins, M.D.: has or has received research funding from NIH, Administration for Children and Families, and the Department of Justice.
  • Christopher Thomas, M.D.: serves on the Accreditation Council for Graduate Medical Education

Cultural Competency

  • John Sargent: has no leadership or financial conflicts to disclose.
  • Ian Canino: has no leadership or financial conflicts to disclose.
  • Terry Cross: has no leadership or financial conflicts to disclose.
  • Mario Hernandez: serves or has served on the Board of the National Latino Behavioral Health Associaton.
  • Kathlene Trello-Rishel: has no leadership or financial conflicts to disclose.
  • Gabrielle Shapiro: serves on the board of the Medical Society of the State of New York.
  • Steve Adelsheim: serves or has served on the National Advisory Committee for the Robert Wood Johnson Foundation Local Funding Partnership Grants; serves or has served on the advisory board for the Center for School Mental Health at the University of Maryland, and receives or has received grant funding from NIMH and SAMHSA.
  • Warren Ng: has no leadership or financial conflicts to disclose.

Depressive Disorders

  • Jeffrey Bridge, Ph.D.:  TBD
  • Amy Cheung, M.D.:  TBD
  • Greg Clarke, Ph.D.:  TBD
  • Graham Emslie M.D.: receives or has received research support from Eli Lilly, Organon, and Forest Laboraties, serves or has served as a consultant for Eli Lilly, GlaxoSmithKline, Wyeth-Ayerst, and Biobehavioral Diagnostics Inc., and has served or is serving on the speaker's bureau for McNeil Pharmaceuticals.
  • Philip Hazell, M.D.:  serves or has served on Advisory Boards for Lilly and Novartis, serves or has served on the speaker's bureau's for Lilly and Janssen, and receives or has received research support from Lilly. Dr. Hazell also has or has had intellectual property with the British Medical Journal Publishing Group.
  • Michael Houston, M.D.: President of the Washington Psychiatric Association and on the board of Directors for the Federation for Families for Children's Mental Health.
  • Stan Kutcher, M.D.: serves or has served on the board of Canadian Psychiatric Research Foundation, the Canadian Society for International Health, and Interhealth Canada.
  • Laura Mufson, Ph.D.: no conflicts of interest to disclose
  • Syed Naqvi, M.D.: received the young investigator award from NARSAD, received a research grant to study the role of PUFA in Adolescent Depression, acted as a consultant and/or served on a speaker's bureau for Jansen Pharmaceuticals, The Medical Education Speakers Network, and an independent medical speaker's bureau for CME professionals.
  • Kelly Posner, Ph.D.: TBD
  • Joseph Rey, M.D.: no conflicts of interest to disclose
  • Karen Wagner, M.D.: TBD
  • Elizabeth Weller, M.D.:TBD

Disaster Preparedness

  • Lisa Amaya-Jackson, M.D., MPH: serves as Associate Director of the Center for Child and Family Health (CCFH). She has or has received research funding from the Duke Evidence-based Practice Implementation Center and CCFH.
  • Stephen J. Cozza M.D.: has no financial conflicts of interest to disclose.
  • David J. Schonfeld, M.D.: has or has received organizational funding from the New York Life Foundation. He serves or has served as an advisor to Procter & Gamble. He has intellectual property with Brookes Publishing.
  • Merritt D. Schreiber, Ph.D.: has no financial conflicts of interest to disclose.
  • Leslie H. Wind, Ph.D.: has no financial conflicts of interest to disclose.
  • Siham Muntasser, M.D.: has no financial conflicts of interest to disclose.
  • Rebecca Susan Daily, M.D.: has no financial conflicts of interest to disclose.
  • D. Richard Martini, M.D.: has no financial conflicts of interest to disclose.
  • Margaret Stuber, M.D.: has no financial conflicts of interest to disclose.

Family Assessment

  • Eugene Beresin, M.D.: no conflicts of interest to disclose
  • Lee Combrinck-Graham, M.D.: no conflicts of interest to disclose
  • Geri Fox, M.D.: no conflicts of interest to disclose
  • Rao Gogineni, M.D.: no conflicts of interest to disclose
  • Gordon Hodas, M.D.: no conflicts of interest to disclose
  • David Kaye, M.D.: receives or has received research funding from Pfizer, Inc.
  • David Keith, M.D.: TBD
  • Douglas Kramer, M.D.: TBD
  • Charles Malone, M.D.: no conflicts of interest to disclose
  • Beatrice Wood, Ph.D.: TBD

Forensic Evaluations

  • William Bernet, M.D. has no financial relationships to disclose.
  • Peter Ash, M.D. has no financial relationships to disclose. He serves on the board of the American Academy of Psychiatry and the Law and is the director of Psychiatry and Law Service at Emory University.
  • Joseph Penn, M.D. has no financial relationships to disclose. He serves on the board of the National Commission on Correctional Healthcare.
  • John Sikorski, M.D.: has no financial relationships to disclose.
  • Judith A. Cohen, M.D.: has or has received research funding from NIMH, SAMHSA, and the Annie E. Casey Foundation. She has intellectual property with Guilford Press.
  • David Fassler, M.D.: has no financial relationships to disclose.
  • Jenna Saul, M.D.: serves or has served on the speakers’ bureau for Shire.
  • Alice Mao, M.D.: serves or has served as an advisor/consultant to Lilly, Novartis, McNeil, and Shire. She serves or has served on the speakers’ bureau for Bristol Myers.
  • Gabrielle Shapiro, M.D.: has no financial relationships to disclose

Gay, Lesbian, Bisexual, Transgender Youth

  • Richard Pleak, M.D.: has no financial conflicts of interest to disclose.
  • Beth Belkin, M.D., Ph.D.: has no financial conflicts of interest to disclose.
  • Sarah E. Herbert, M.D., MSW: has no financial conflicts of interest to disclose.
  • Ledro R. Justice, M.D.: has no financial conflicts of interest to disclose.
  • Scott Leibowitz, M.D.: has no financial conflicts of interest to disclose.
  • Edgardo J. Menvielle, M.D.: has no financial conflicts of interest to disclose.
  • Yiu Kee Warren Ng, M.D.: has no financial conflicts of interest to disclose.
  • R. Kaan Ozbayrak, M.D.: owns iPsych.net.
  • Joel J. Stoddard, M.D.: has no financial conflicts of interest to disclose.
  • William M. Womack, M.D.: is on the American Psychiatric Association's Board of Trustees and DSM-V Task Force.
  • Deborah Carter, M.D.: has no financial conflicts of interest to disclose.
  • Jennifer I. Downey, M.D.: has no financial conflicts of interest to disclose.
  • James Farrow, M.D.: has no financial conflicts of interest to disclose.
  • Richard C. Friedman, M.D.: has no financial conflicts of interest to disclose.
  • Heino F. L. Meyer-Bahlburg, Dr. rer. nat.: has no financial conflicts of interest to disclose.
  • Cynthia Telingator, M.D.: has no financial conflicts of interest to disclose.
  • Kathleen Trello-Rishel, M.D.: has no financial conflicts of interest to disclose.
  • Kathleen Kelley, M.D.: has no financial conflicts of interest to disclose.
  • Melvin Oatis, M.D.: has no financial conflicts of interest to disclose.
  • Theodore Petti, M.D.: has no financial conflicts of interest to disclose.
  • Gerald Dabbs, M.D.: has no financial conflicts of interest to disclose.

Obsessive Compulsive Disorders

  • Marco Grados, M.D. has no conflicts of interest to disclose.
  • Gregory Hanna, M.D. has or has received research funding from NIMH. Aude Henin, Ph.D. has served as an advisor or consultant to Pfizer, has intellectual property with Oxford University Press, and received
  • honoraria from Shire, Abbot, and Reed Medical Education.
  • Isobel Heyman, MBBS, FRACPsych has or has had intellectual property with Jessica Kingsley Publisher.
  • James Leckman, M.D. has or has received research funding from the NIH, been an advisor or consultant to the NIH, NARSAD, NORD, and American Psychiatric Association, has been a member of the
  • speakers bureau for the Tourette Syndrome Association, and has intellectual property with John Wiley and Sons, McGraw Hill, and Oxford University Press.
  • Gabriele Masi, M.D. has or has received research funding from Eli Lilly; serves or has served as an advisor for Eli Lilly and Shire; and serves or has served on speakers’ bureaus for Sanofi Aventis, Astra
  • Zeneca, GSK, and Janssen.
  • Euripides Miguel, M.D. has lectured with or at Solvay and Lundbeck.
  • Janardhan Reddy, M.D., DPM has no conflicts of interest to disclose.
  • Aline Sampaio, M.D. has no conflicts of interest to disclose.
  • S. Evelyn Stewart, M.D. has no conflicts of interest to disclose.
  • Eric Storch, Ph.D. has or has received research funding from NIMH, NICHD, Foundation for Prader-Willi Research, Tourette Syndrome Association, CDC, Ortho McNeil Pharmaceuticals, AU Children’s Hospital
  • Research Foundation.
  • Karen Wagner, M.D. has received or receives research funding from NIMH, has been part of a review panel for American Institute of Biological Sciences, has been an advisor/consultant for Forest, and
  • received honoraria from Health Wellness Educational Partners, APA, American Psychiatric Publishing, Physicians Post Graduate Press, CMP Medica, Letters and Sciences.
  • Efrain Bleiberg, M.D.: has no conflicts of interest to disclose.
  • Johnny Lops, D.O.: has no conflicts of interest to disclose.
  • Catherine Anne Steele, M.D.: has no conflicts of interes

Post Traumatic Stress Disorder

  • Lisa Amaya-Jackson: receives or has received research support from the Substance Abuse and Mental Health Services Administration (SAMHSA).
  • Jeanne Bereiter: has no financial relationships to disclose.
  • Nancy Black: has no financial relationships to disclose.
  • Efrain Bleiberg: is an officer of the Society of Professors of Child and Adolescent Psychiatry. He has no financial relationships to disclose.
  • Michael De Bellis: receives or has received research support from the National Institutes of Health (NIH).
  • Gail Edelsohn: has no financial relationship to disclose.
  • Helen Egger: TBD.
  • Paramjit Joshi: serves on the American Board of Psychiatry and Neurology. She has no financial relationships to disclose.
  • Anthony Mannarino: receives or has received research support from the National Institutes of Health (NIH) and the Substance Abuse and Mental Health Services Administration (SAMHSA). He has a book published with Guilford Press. He is a Section President of the American Psychological Association.
  • Yiu Kee Warren Ng: has no financial relationship to disclose.
  • Frank Putnam: serves as a Trustee of the Ohio Children's Trust Fund. He has no financial relationships to disclose.
  • Robert Pynoos: has no financial relationships to disclose.
  • Ken Rogers: has no financial relationships to disclose.
  • Michael Scheeringa: has no financial relationships to disclose.
  • Susan Scherer: has no financial relationships to disclose.

Psychodynamic Psychotherapy with Children

  • Rachel Ritvo, M.D.: has no financial conflicts of interest to disclose.
  • Helene Keable, M.D.: has no financial conflicts of interest to disclose.
  • Aaron Esman, M.D.: has no financial conflicts of interest to disclose.
  • Edward Sperling, M.D.: has no financial conflicts of interest to disclose.
  • Robert Tyson, M.D.: has no financial conflicts of interest to disclose.
  • Clarice Kestenbaum, M.D.: has no financial conflicts of interest to disclose.
  • Andrew Gerber, M.D.: has or has served as chair of the American Psychiatric Association's Committee for Scientific Activities.
  • Samuel Rubin, M.D.: has no financial conflicts of interest to disclose.
  • Ted Shapiro, M.D.: failed to disclose any potential conflicts of interest.
  • Sandra Sexson, M.D.: has no financial conflicts of interest to disclose.
  • Marty Drell, M.D.: has no financial conflicts of interest to disclose.

Psychotropic Medications

  • Larry Greenhill, M.D.: receives or has received research support from Otsuka, Johnson and Johnson, and the National Institute of Mental Health (NIMH).
  • Christopher Kratochvil, M.D.: receives or has received research support, acted as a consultant for: Eli Lilly and Company; Shire Pharmaceutical Inc.; Abbott; and Somerset Pharmaceutical Inc. Is/was Member of the Data and Safety Monitoring Board (DSMB) for Pfizer.
  • Aradhana Bela Sood:M.D.: Member of the VA state board of social services, AACAP assembly, AACAP council. Chair of VCU division of child psychiatry.
  • Mark Riddle, M.D.: no conflicts of interest to disclose
  • Timothy Wilens, M.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for: Abbott Laboratories; Cephalon, Inc.; Ortho-McNeil ; Eli Lilly and Company; National Institute on Drug Abuse; Neurosearch; Shire Laboratories, Inc.; Novartis Pharmaceutical Corporation, Janssen, L.P.; National Institute on Mental Health; and Pfizer, Inc.
  • Charles H. Zeanah, M.D.: has or has had books/intellectual property with Guilford Press.
  • Susan Daily, M.D.: serves or has served on speaker’s bureau for Forrest and BMS.
  • Daniel S. Pine. M.D.: Research scientist at the National Institute of Health (NIH). Deputy Editor of the American Journal of Psychiatry. Gave lectures for various CME programs.

Schizophrenia

  • Nitin Gogtay, M.D.: has no financial conflicts of interest to disclose.
  • Robert Findling, M.D.: has or has received grant funding or other research support from Abbott Laboratories, Addrenex Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Neuropharm, Otsuka Pharmaceutical Co, Ltd., Pfizer, Inc., Rhodes Pharmaceuticals, Schering-Plough, Shire, Supernus Pharmaceuticals, and Wyeth. He serves or has served as a consultant to the entities listed above, with the exception of Neuropharm and Rhodes Pharmaceuticals, as well as Alexza Pharmaceuticals, Biovail, KemPharm, Inc., Lundbeck, Novartis AG, Noven Pharmaceuticals, Inc., Organon, Sanofi-Aventis, Seaside Therapeutics, Solvay, Sunovion Pharmaceuticals, Inc., Transcept Pharmaceuticals, Validus, and WebMD. He serves or has served on the speakers bureau of Bristol-Myers Squibb, Johnson & Johnson, and Shire. He has intellectual property with American Psychiatric Press, Guilford Press, Johns Hopkins University Press, Sage, and WebMD.
  • Benedetto Vitiello, M.D.: has no financial conflicts of interest to disclose.
  • Melissa Del Bello, M.D.: has or has had research funding from AstraZeneca, Eli Lilly, Johnson & Johnson, Janssen, Pfizer, Otsuka, Sumitomo, NIDA, NIMH, NIAAA, NARSAD, GlaxoSmithKline, Merck, Novartis, and Lundbeck. She serves or has served on speakers bureau of Bristol-Myers Squibb and Merck. She has consulted for, served on an advisory board for, or received honoraria from Merck, Schering-Plough, and Pfizer.
  • George Realmuto, M.D.: has no financial conflicts of interest to disclose.
  • Nilda Gonzalez, M.D.: has no financial conflicts of interest to disclose.
  • Mark Borer, M.D.: has no financial conflicts of interest to disclose.
  • Steve Adelsheim: has or has received research funding from NIMH.

Tic Disorders

  • Barbara Coffey – serves or has served on the speakers bureau for the Tourette Syndrome Association CDC Partnership; has or has received research funding from Otsuka Pharmaceuticals, Shire, Pfizer, Catalyst, NIMH, NINDS.
  • Carol Mathews – serves or has served on the Medical Advisory Board for the National Tourette Syndrome Association; has or has received grant support from NIH.
  • Cathy Budman – serves or has served on the Advisory Boards for Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) Long Island, Long Island Tourette Syndrome Association, and National Tourette Syndrome Association; has or has received grant support from National Institutes of Health and Psyadon Pharmaceuticals, Inc.; has or has received research support from Otsuka America Pharmaceutical, Inc. in 2011.
  • James Leckman – has no financial conflicts of interest to disclose.
  • Michael Bloch – has no financial conflicts of interest to disclose.
  • Jonathan Mink – receives grant support from NINDS, CDC, and FDAl serves as Associate Editor of Neurology from the American Academy of Neurology, serves on the Data and Safety Monitoring Board for Edison Pharmaceuticals, and serves as Chair, Scientific Advisory Board TSA.
  • Melissa Del Bello, M.D. - has or had research funding from AstraZeneca, Eli Lilly, Johnson & Johnson, Janssen, Pfizer, Otsuka, Sumitomo, NIDA, NIMH, NIAAA, NARSAD, GlaxoSmithKline, Merck, Novartis, and Lundbeck. She serves or has served on speakers bureau of Bristol-Myers Squibb and Merck. She has consulted for, served on an advisory board for, or received honoraria from Merck, Schering-Plough, and Pfizer.
  • Debra Koss, M.D. - has no financial conflicts of interest to disclose.
  • Felissa Goldstein, M.D. - serves as an advisor or consultant to Alliant/GMCF.
  • David DeMaso, M.D. - serves on a speakers bureau and receives royalties from APPI, Inc.
  • Jenna Saul, M.D. - has no financial conflicts of interest to disclose.

Committee (formerly Work Group) on Quality Issues

  • Valerie Arnold, M.D.: TBD
  • Joseph Beitchman, M.D.: no conflicts of interest to disclose
  • Christopher Bellonci, M.D.: is a consultant to the Annie E. Casey Foundation.
  • Scott Benson, M.D.: no conflicts of interest to disclose
  • Allan Chrisman, M.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Shire Pharmaceuticals Group plc, McNeil Pediatrics, Novartis Pharmaceuticals Corporation, Eli Lilly and Company,Otsuka, SUpernus,  Pfizer Inc., Addrenex Pharmaceuticals, MediSpin, NIMH, NIEHS, NIDA. Dr. Chrisman has or has had books/intellectual property with Castle Connely.
  • Tiffany Farchione, M.D.: no conflicts of interest to disclose
  • John Hamilton, M.D.: senior physician and shareholder in The Permanente Medical Group of California, Inc.
  • Helene Keable, M.D.: no conflicts of interest to disclose
  • Joan Kinlan, M.D.: no conflicts of interest to disclose
  • Jon McClellan, M.D.: receives or has received research funding from Pfizer Inc.
  • Nicole Quiterio, M.D.: no conflicts of interest to disclose
  • David Rue, M.D.: no conflicts of interest to disclose
  • Ulrich Schoettle, M.D.: no conflicts of interest to disclose
  • Jon Shaw, M.D.: no conflicts of interest to disclose
  • Matthew Siegel, M.D.: no conflicts of interest to disclose
  • Saundra Stock, M.D.: receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Abbott Laboratories, Janssen, L.P., Bristol-Myers Squibb, Ortho-McNeil, and GlaxoSmithKline.